Project Grant R35GM167080
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $419,939 on August 1, 2026, to conduct live-cell super-resolution imaging research on enhancer-mediated gene bursting under the Biomedical Research and Research Training program (CFDA 93.859). The research characterizes transcriptional condensates—assemblies of RNA Polymerase II, Mediator, and transcription activators—in mouse embryonic stem cells and examines how they regulate target gene expression...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $407,603 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate brain-body allostasis via longitudinal in vivo imaging. The research examines how astrocytes—non-neuronal glial cells in the brain—coordinate physiological state shifts and facilitate whole-body allostasis during stress response. The study uses simultaneous in vivo recording of...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $400,969 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop phenotype control methods for guided manipulation of cell behavior and fate. The research advances two phenotype control approaches applicable to biomolecular systems. Feedback Vertex Set (FVS) Control, based on interaction networks underlying biological systems, will be refined to overcome the...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $440,259 in a Project Grant (R35GM163932) on September 1, 2026, to investigate the mechanobiology of epithelial-mesenchymal plasticity. The research examines how combined effects of matrix elasticity and viscosity regulate epithelial cell plasticity and fate decisions in response to transforming growth factor (TGF)-β1 stimulation. The project synthesizes and characterizes hydrogels with independent and...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $393,250 on March 9, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support the Burghardt Lab's investigation of the genomic basis of facultative host-microbe mutualism. The research probes how host genes influence microbial adaptation and the persistence of mutualistic symbiosis in nature, using whole-genome sequencing, bioinformatics tools, and field and laboratory...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $750,554 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms and control of oxygen and carbon-hydrogen activation within enzyme architectures. The award supports a five-year project through March 31, 2031, with performance at Penn State's State College, Pennsylvania campus. The research program examines three classes of metalloenzymes that...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $432,575 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and validate technologies for controlled three-dimensional protein condensation to improve cryo-electron tomography sample preparation. The project addresses air-water interface damage that compromises sample quality and limits cryo-EM applications to many biological systems. The recipient...
- The National Institute of General Medical Sciences awarded The Trustees of the University of Pennsylvania $446,875 on March 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to characterize the molecular determinants of voltage-gated ion channel localization and function. The project investigates how the Golgi-associated phosphoprotein 3 (GOLPH3) coordinates transport, stability, and activity of voltage-gated sodium and potassium channels at the cell plasma...
- The National Institute of General Medical Sciences awarded The Pennsylvania State University $425,667 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms of chromatin remodeling and histone deacetylation. The recipient's research program examines ATP-dependent chromatin remodelers, specifically CHD and ISWI ATPases, and sirtuins, NAD-dependent histone deacetylases, two enzyme families that dynamically regulate...
- The National Institute of General Medical Sciences awarded the University of Pennsylvania $924,095 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular mechanisms controlling actin cytoskeleton dynamics. The research addresses four major knowledge gaps: the ARP2/3 complex's role in actin filament branching and regulation by nucleotide state and binding proteins; filament dynamics at barbed and pointed ends, including cooperative...
The National Institute of General Medical Sciences awarded The Pennsylvania State University $432,575 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular pharmacology and physiology of ghrelin receptor functional selectivity. The research examines two clinically relevant principles of G protein-coupled receptor (GPCR) pharmacology: functional selectivity (the asymmetric engagement of intracellular transducers such as G proteins or β-arrestin, leading to preferential activation of specific downstream effector pathways) and allosteric modulation (biophysical interactions at receptor sites topographically distinct from the endogenous ligand or transducer). The work addresses the gap between understanding these molecular processes at the cellular level and their culmination into disease-relevant physiological effects at the organismal level. The research plan tackles two overarching questions: what evolutionarily conserved receptor loci regulate the spatial distribution, trafficking fates, transducer coupling selectivity, and downstream physiological responses of rhodopsin-like GPCRs, and what ligand binding mechanisms enable functional selectivity and allosteric modulation. Work is performed in State College, Pennsylvania. The award period runs from August 1, 2026, through March 31, 2031. This is a Project Grant, the standard assistance type for investigator-initiated research under the NIGMS portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $432.6k | 7/30/26 |